IGF-1 LR3 1mg · EU Stock, No Customs

Zoom

59,00 €

Tax included • Free delivery from 99€

+2,95 € in loyalty cashback, with an account. Create my account

Only 9 left, flying off the shelf!

Next dispatch: Saturday, October 3

In stock in France

Subscription

53,10 €-10 %instead of 59,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

Your complete kit

1mg vialIncluded
Bacteriostatic waterAdd
1 ml syringesAdd

The vial alone cannot be used as is. One sealed vial of IGF-1 LR3 1mg, lyophilised, without individual labelling.

Don't forget the essentials

Eau Bactériostatique

7,90 €

Seringue de précision 1ml 29Gx107,90 €

Lingettes alcool isopropylique 70%x103,90 €

Frequently bought together

GHK-Cu 100mg49,00 €

IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is a synthetic analogue of human IGF-1, with 83 amino acids against 70 for the native molecule. Two modifications set it apart: a 13-amino-acid N-terminal extension and the substitution of glutamic acid at position 3 with arginine (hence "R3").

Both changes target the same thing: affinity for the IGFBPs, the six binding proteins that sequester circulating IGF-1. Native IGF-1 is over 95% bound and its free plasma half-life is measured in minutes. The LR3 analogue binds them weakly and stays available far longer — that is the entire rationale for this research version.

This vial delivers 1 mg of IGF-1 LR3 at HPLC purity of at least 98%, lyophilised in type I borosilicate glass. For research use only.

Science

01
Mechanism of action

IGF-1 acts on the IGF-1R receptor, a transmembrane tyrosine kinase of the insulin receptor family. Binding triggers receptor autophosphorylation and then two main cascades: the PI3K/Akt/mTOR pathway, associated in the literature with protein synthesis and cell survival, and the MAPK/ERK pathway, associated with proliferation.

What sets LR3 apart is not mechanistic but pharmacokinetic. The IGFBPs, particularly IGFBP-3, form a ternary complex with native IGF-1 that extends its circulating presence while making it unavailable. By reducing that binding, the LR3 analogue increases the free fraction — the amount of molecule actually able to reach the receptor.

Worth noting, as it is a common confusion: reduced IGFBP affinity does not mean increased receptor affinity. LR3 binds IGF-1R with comparable, if slightly lower, affinity than native IGF-1.

Clinical data

02Clinical studies

IGF-1 is one of the best-characterised growth factors in the biomedical literature, with several decades of work on its role in growth, glucose metabolism and muscle physiology. Mecasermin, recombinant human IGF-1, holds marketing authorisation for severe primary IGF-1 deficiency, which gives the native molecule a solid pharmacological foundation.

The LR3 analogue, however, was developed and is still overwhelmingly used as a laboratory tool, notably in cell culture where it is widely employed as a medium supplement: its low IGFBP affinity is a direct advantage there, since the binding proteins present in serum would neutralise added native IGF-1.

There is no human clinical trial on IGF-1 LR3, and no authority has evaluated it for therapeutic use. Available data are preclinical, in vitro or animal, and that is the framework in which this product is sold.

No references yet for this peptide — search PubMed for associated scientific literature.

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Reconstitution. The 1 mg vial is reconstituted with 1 ml of bacteriostatic water, giving a 1 mg/ml solution, i.e. 1,000 mcg/ml. On a U-100 insulin syringe, 1 unit then equals 10 mcg, which makes small volumes readable without any calculation.

Procedure: let the vial return to room temperature, disinfect the septum with 70% isopropyl alcohol, inject the water slowly along the inner wall and never directly onto the lyophilised cake, then gently roll the vial between your palms until dissolved. Never shake: the peptide's tertiary structure and its three disulfide bridges are sensitive to it.

On acetic acid. Part of the laboratory literature reconstitutes IGF-1 LR3 in dilute acetic acid (0.6%) for extended storage stability. We do not sell that solvent, and bacteriostatic water is adequate for ordinary use periods; it is a protocol choice, to be documented by the researcher.

Reported orders of magnitude. Research literature typically mentions quantities of 20 to 50 mcg per administration, i.e. 2 to 5 units on a U-100 syringe at this concentration. A 1 mg vial therefore represents 20 to 50 administrations depending on the scheme used. These figures are reported, not recommended.

Reconstitution for this format (1 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
1 ml	1 mg/ml	40 UI = 0,4 mg
2 ml	0,5 mg/ml	40 UI = 0,2 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Unreconstituted lyophilised vial: stable for several months between 2 and 8 °C, several years in a -20 °C freezer, protected from light. Ambient-temperature transport does not degrade it: the lyophilisate is designed to withstand far more than the duration of a shipment.

After reconstitution: refrigerated between 2 and 8 °C, protected from light. Bacteriostatic water, containing 0.9% benzyl alcohol, allows repeated draws over several weeks. Never freeze a reconstituted solution: a freeze-thaw cycle denatures the peptide even if the solution looks normal afterwards.

A light, uniform haze may appear after reconstitution; it is particles in suspension, a deposit that will not redissolve, or a yellow colour that justify discarding a vial.

01How much water to reconstitute the 1 mg vial?

1 ml of bacteriostatic water, giving 1 mg/ml or 1,000 mcg/ml. On a U-100 syringe, 1 unit then equals 10 mcg: 20 mcg reads as 2 units, 50 mcg as 5 units. It is the most readable concentration for a vial of this size.

02Should I use acetic acid rather than bacteriostatic water?

Part of the laboratory literature uses it, at 0.6%, for long-term storage. We do not sell that solvent. For ordinary use periods, bacteriostatic water is adequate and has the advantage of a preservative allowing repeated draws. It is a protocol choice.

03What is the difference with classic IGF-1?

Availability. Native IGF-1 is over 95% bound by IGFBP transport proteins and its free half-life is measured in minutes. LR3, through its N-terminal extension and Arg3 substitution, binds them weakly and stays available far longer. The target receptor is the same.

04Are there clinical trials on IGF-1 LR3?

No. There is no human clinical trial on IGF-1 LR3, and no authority has evaluated it for therapeutic use. The clinical record belongs to native IGF-1: mecasermin, recombinant human IGF-1, is authorised for severe primary IGF-1 deficiency. LR3 was developed as a laboratory tool and is mainly used as a cell-culture supplement. Its data are preclinical, in vitro or animal, and that is the framework in which this product is sold.

05How many draws does a 1 mg vial represent?

1 mg is 1,000 mcg. At the quantities reported in the literature, 20 to 50 mcg per administration, a vial therefore represents 20 to 50 draws. Actual autonomy depends entirely on the scheme chosen by the researcher.

06Can it be combined with a secretagogue such as CJC-1295 or Ipamorelin?

These are two different levels of action: secretagogues stimulate growth hormone release upstream, IGF-1 LR3 acts downstream on the receptor. Research literature documents both separately and we do not offer a combined protocol, which is not established.

07Must the solution be perfectly clear?

A light, uniform haze may appear and is not a defect. What justifies discarding a vial is particles that stay in suspension, a deposit that will not redissolve despite cold rest, or a yellow colour.

Benchmark

Similar peptides

Against native IGF-1 (mecasermin). Same receptor, same cascade, but incomparable availability: native IGF-1 is over 95% sequestered by IGFBPs, LR3 largely escapes them. That is the only difference that matters in practice, and it is pharmacokinetic.

Against secretagogues (Ipamorelin, CJC-1295, Tesamorelin). The difference is one of level. Secretagogues act upstream: they stimulate the pituitary to release growth hormone, which then drives hepatic IGF-1 production. They therefore preserve physiological pulsatility and feedback loops. IGF-1 LR3 bypasses that chain and acts downstream, directly on the receptor. The two approaches are not interchangeable and are not documented in the same way.

Against MGF and PEG-MGF. MGF is a splice isoform of IGF-1, with a different E domain and local action; its pegylated form seeks to extend a naturally very short half-life. These are neighbouring but distinct molecules, with separate literatures.

IGF-1 LR3 1mg Croissance musculaire

Growth Factors

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Growth Factors

Product information

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents